Geode Capital Management LLC Has $48.79 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Geode Capital Management LLC boosted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 14.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,153,325 shares of the company's stock after purchasing an additional 148,660 shares during the period. Geode Capital Management LLC owned about 1.82% of Vera Therapeutics worth $48,787,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. AlphaQuest LLC acquired a new stake in Vera Therapeutics during the 4th quarter valued at $34,000. KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares during the period. Moors & Cabot Inc. acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth about $220,000. E Fund Management Co. Ltd. boosted its holdings in shares of Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock worth $262,000 after buying an additional 1,130 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Vera Therapeutics in the 4th quarter valued at about $431,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VERA shares. Guggenheim raised their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price for the company. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Vera Therapeutics has an average rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Price Performance

Shares of VERA stock traded up $0.05 during trading hours on Friday, reaching $21.29. The company's stock had a trading volume of 661,231 shares, compared to its average volume of 747,566. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm's 50 day simple moving average is $26.09 and its 200-day simple moving average is $36.50. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.